Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma
Londres; NICE; May 3, 2023. 26 p.
Não convencional
em Inglês
| BIGG - guias GRADE
| ID: biblio-1434652
Biblioteca responsável:
BR1.1
ABSTRACT
People with relapsed or refractory diffuse large B-cell lymphoma who cannot have an autologous stem cell transplant usually have polatuzumab vedotin plus rituximab and bendamustine. The clinical evidence is from a small study that did not directly compare tafasitamab plus lenalidomide with any other treatment. The committee considered that the study results were promising because they show that some people's disease responds to tafasitamab plus lenalidomide. Indirect evidence suggests that people who have tafasitamab plus lenalidomide have more time before their disease gets worse than people who have polatuzumab vedotin plus rituximab and bendamustine. It also suggests that they live longer. But there is uncertainty about these results because the survival times for people having polatuzumab vedotin plus rituximab and bendamustine used in the modelling do not reflect the real-world survival times of the treatment in clinical practice, compared with bendamustine and rituximab alone. The methods used for the indirect comparisons are also not clear.
Texto completo:
Disponível
Coleções:
Bases de dados temática
Base de dados:
BIGG - guias GRADE
Assunto principal:
Linfoma Difuso de Grandes Células B
Tipo de estudo:
Guia de prática clínica
/
Estudo prognóstico
Idioma:
Inglês
Ano de publicação:
2023
Tipo de documento:
Não convencional